Lancet Psychiatry
November 1, 2022
Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jan Spijker et al.
163 citations
Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its efficacy, safety, and tolerability in depression. We searched Pubmed, Embase, and the Cochrane Library and identified three randomised...
Lancet Psychiatry
May 1, 2022
Rosa Ritunnano, Joshua J. Kleinman, Danniella Whyte Oshodi et al.
BACKGROUND Delusions are a common transdiagnostic feature of psychotic disorders, and their treatment remains suboptimal. Despite the pressing need to better understand the nature, meaning, and course of these symptoms, research into the lived experience of delusional phenomena in psychosis is scarce. Thus, we aimed to explore the lived experience and subjective apprehension of delusions in...
Lancet Psychiatry
October 1, 2020
Brian T Anderson, Alicia Danforth, Charles S. Grob
99 citations
Psychedelic medicine: safety and ethical concerns.
Lancet Psychiatry
May 1, 2018
Michael C Mithoefer, Ann T Mithoefer, Allison A. Feduccia et al.
443 citations
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Lancet Psychiatry
2018
Brooke L Short, J. Fong, V. Galvez et al.
551 citations
This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and Cochrane Databases and identified 288 articles, 60 of which met the inclusion criteria. After acute dosing, psychiatric, psychotomimetic, cardiovascular, neurological, and other side-effects were more frequently reported after...
Lancet Psychiatry
May 1, 2017
I. Anderson, A. Blamire, T. Branton et al.
106 citations
Summary Background The use of electroconvulsive therapy (ECT) is limited by concerns about its cognitive adverse effects. Preliminary evidence suggests that administering the glutamate antagonist ketamine with ECT might alleviate cognitive adverse effects and accelerate symptomatic improvement; we tested this in a randomised trial of low-dose ketamine. Methods In this multicentre, randomised,...
Lancet Psychiatry
April 5, 2017
Ilina Singh, Celia J. A. Morgan, Valerie H. Curran et al.
158 citations
We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does...
Lancet Psychiatry
September 1, 2016
Robin Carhart-Harris, David Nutt
1 citation
Question-based Drug Development for psilocybin - Authors' reply.
Lancet Psychiatry
May 17, 2016
Robin Carhart-Harris, Mark Bolstridge, James Rucker et al.
1,546 citations
BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy...
Lancet Psychiatry
April 5, 2016
Michael C Mithoefer, Charles S. Grob, Timothy D Brewerton
237 citations
4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as...